60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Investing.com - Piper Sandler has reiterated an Overweight rating on Edwards Lifesciences (NYSE:EW) with a price target of $95.00 ahead of the company’s annual investor day. The stock currently trades at $84.39, near its 52-week high of $87.20, with 15 analysts having revised their earnings upwards for the upcoming period according to InvestingPro data.
The medical device maker will host its investor day on December 4, where Piper Sandler expects management to reiterate its fiscal year 2025 outlook and provide initial guidance for fiscal year 2026.
The research firm anticipates Edwards Lifesciences’ 2026 revenue and adjusted earnings per share guidance will align with current market consensus, with the midpoints generally matching Street expectations. The company has demonstrated solid performance with 10.6% revenue growth over the last twelve months, though it trades at a relatively high P/E ratio of 36.95.
Piper Sandler expects significant discussion about Edwards’ U.S. TAVR (Transcatheter Aortic Valve Replacement) franchise, noting recent improvements, PARTNER 3 seven-year data, and pending NCD (National Coverage Determination) reopening.
The firm also anticipates focus on Edwards’ TMTT (Transcatheter Mitral and Tricuspid Technologies) program, which it projects could drive more than 300 basis points of annual growth in coming years.
In other recent news, Edwards Lifesciences reported robust financial results for the third quarter of 2025, surpassing Wall Street expectations. The company achieved an adjusted earnings per share of $0.67, exceeding the forecasted $0.59, and reported revenue of $1.55 billion, which was higher than the anticipated $1.5 billion. This strong performance was marked by a 12.6% year-over-year adjusted growth in sales, with the transcatheter aortic valve replacement (TAVR) business showing over 10% growth. Following these results, Bernstein raised its price target for Edwards Lifesciences to $90, citing the impressive growth in the TAVR segment. Canaccord Genuity also increased its price target to $84, noting the company’s strong quarterly performance. Additionally, Raymond James upgraded Edwards Lifesciences from Market Perform to Outperform, setting a price target of $96. These developments reflect a positive sentiment among analysts regarding the company’s recent achievements and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.